<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28564">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096016</url>
  </required_header>
  <id_info>
    <org_study_id>Follow-up</org_study_id>
    <secondary_id>1-10-72-321-13</secondary_id>
    <nct_id>NCT02096016</nct_id>
  </id_info>
  <brief_title>HPV-test, Cervical Cancer and Follow-up</brief_title>
  <official_title>Recurrence After Surgery for Cervical Cancer - an Evaluation of the Follow-up Program.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: National Board of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have planned this project to evaluate the follow-up program after surgery
      due to cervical cancer and to explore the possibilities for different tests of Human
      Papilloma Virus (HPV) in contributing to the customization of the follow-up program.

      Purpose:

      The investigators effort is to provide the background for an evidence-based update of the
      follow-up program after surgery due to cervical cancer with the purpose of early diagnosis
      of recurrence affecting quality of life for as few women as possible.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Prevalence of HPV Genotypes in Vagina (Type 16, 18 and Other)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HPV Clearance From Vagina in Between the Two Planned Follow-up Visits.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate 1-year, 2-year and 5-year Recurrence</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HPV</condition>
  <condition>Cervical Cancer</condition>
  <condition>Surveillance</condition>
  <condition>Follow-up</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Primary surgical treatment for cervical cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HPV test from vagina three and twelve months after surgery</intervention_name>
    <arm_group_label>Primary surgical treatment for cervical cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated for cervical cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgery. FIGO stage IA-IB. &gt; 18 years

        Exclusion Criteria:

          -  Ajuvant oncologic treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katrine Fuglsang, MD</last_name>
    <email>katrine.fuglsang@ki.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuglsang</last_name>
      <email>katrine.fuglsang@ki.au.dk</email>
    </contact>
    <investigator>
      <last_name>Fuglsang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuglsang</last_name>
      <email>katrine.fuglsang@ki.au.dk</email>
    </contact>
    <investigator>
      <last_name>Fuglsang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
